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Participant profiles by influenza B case status among Canadian Sentinel Practitioner Surveillance Network (SPSN) patients, 2010-11 to 2017-18 Table 4 Lineage-specific influenza B vaccine effectiveness (VE), 2010-11 to 2017-18 Table 5 Sensitivity analyses: lineage-specific VE, excluding children and/or the province of Alberta, and for the early and prolonged 2017-18 epidemic Version: September 24, 2018 Table 1 . Virological diagnosis and characterization -methods and details Influenza B was diagnosed by real-time reverse transcription polymerase chain reaction (rRT-PCR) at provincial public health reference laboratories in participating provinces of the Canadian Sentinel Practitioner Surveillance Network (SPSN), including Alberta, British Columbia, Ontario and Quebec [24] [25] [26] [27] [28] [29] . As context for vaccine effectiveness (VE) estimates displayed in the current report, a subset of sentinel virus isolates was further characterized antigenically by hemagglutination inhibition (HI) assay at Canada's National Microbiology Laboratory (NML) using turkey erythrocytes and ferret anti-sera raised against egg-(until and/or cell-passaged (after versions of the vaccine reference strain [12, [24] [25] [26] [27] [28] [29] . Influenza B lineage was determined by a combination of HI assay findings, RT-PCR-based methods 1,2 and, beginning in 2013-14, sequencing of the hemagglutinin (HA) gene from primary patient specimens.
Because only a subset (59%) of influenza B viruses were lineage-characterized in 2010-11, 97% of which were B(Victoria)-lineage [24] , viruses of unknown lineage were re-classified as B(Victoria) and included in VE analysis that season. For all other seasons, most (>90%) of influenza B viruses were lineage-characterized and cases of alternate or unknown lineage were excluded from lineage-specific VE derivation.
Prior to 2013-14 the clade of circulating viruses by season was inferred from HI characterization of SPSN viruses using cell-culture isolates, turkey erythrocytes and postinfection ferret antisera raised against egg-passaged vaccine reference strains [24] [25] [26] , and was further informed by national and global surveillance reports as indicated in Table 1A below. Beginning in 2013-14, genetic clade designation was based on phylogenetic analysis of viral HA sequencing data obtained directly from primary specimens provided by SPSN participants [associated Genbank accession numbers provided in Table 1B below].
Similar to influenza A vaccine strains of both subtypes [13] [14] [15] [16] [17] [18] [19] , candidate influenza B vaccine strains of both lineages [18] [19] [20] [21] [22] [23] , can acquire in vitro mutations with adaptation for eggbased manufacturing, including loss of N-linked glycosylation sites that can variably affect their antigenicity and immunogenicity assessment [15, 17, [18] [19] [20] [21] [22] .
Victoria lineage viruses detected by the SPSN between 2010-11 and 2012-13 that were characterized by HI assay at Canada's NML were considered antigenically related to the eggpassaged clade 1A vaccine reference strain [24] [25] [26] . Globally, circulating viruses of the Victoria lineage were also considered antigenically related to the cell-passaged clade 1A vaccine reference strain, but with more variable antigenic distinction in relation to the egg-adapted vaccine strain [18, 19] . Prior to the 2015-16 season, Victoria clade 1A viruses sequenced by the SPSN had acquired I117V and N129D antigenic site substitutions, defining a major sub-cluster (along with V146I) within clade 1A. Relevance of these mutations is uncertain: characterized SPSN viruses were still considered antigenically similar to the cell-passaged vaccine reference virus but with more variability in relation to the egg-passaged vaccine virus [29] . Thereafter in 2016-17, viruses of the clade 1A group were shown elsewhere (notably the United States) to have acquired a double amino acid deletion (∆) in HA1 antigenic site positions 162-163 (∆162-163) distinguishing them antigenically from the cell-passaged clade 1A vaccine reference virus [18, 19, 30] ; however Victoria viruses did not contribute to lineage-specific VE analyses presented here for 2016-17 or 2017-18.
Yamagata lineage viruses detected by the SPSN and elsewhere during the study period clustered phylogenetically into clades 2 and 3. Many but not all anti-sera were able to antigenically differentiate viruses falling in the alternate clade. In general, anti-sera raised against clade 2 viruses better recognized clade 2 than clade 3 test viruses, and anti-sera raised against clade 3 viruses better recognized clade 3 viruses than did the anti-sera raised against clade 2 viruses. Yamagata clade 2 and clade 3 viruses can likely be considered antigenically distinct, but with some variation in cross-reactivity based on anti-sera used [18, 19] .
We interpret VE findings foremost in the context of phylogenetic clade-and/or lineagelevel relationship between vaccine and epidemic strains.
Version: September 24, 2018 Per phylogenetic analysis of SPSN viruses [28] . Virtually all of the sequenced SPSN clade 3 viruses bore the L172Q substitution and a substantial proportion also bore M251V, both in non-antigenic sites and generally not considered to have conferred antigenic drift. SPSN viruses belonging to clade 3 that were HI-characterized were considered antigenically related to the cell-passaged clade 2 vaccine strain [28] . In general elsewhere, however, anti-sera raised against the clade 2 vaccine strain (cell-or egg-passaged) did not recognize clade 3 test viruses as well as anti-sera raised against a clade 3 reference strain (cell-or egg-passaged) [18, 19] . Clade 2 and clade 3 viruses can likely be considered antigenically distinct but with some variation in cross-reactivity based on anti-sera used [18, 19] . Per phylogenetic analysis of SPSN viruses [29] . Prior to the 2015-16 season, Victoria clade 1A viruses sequenced by the SPSN had acquired I117V and N129D antigenic site substitutions, defining a major sub-cluster (along with V146I). SPSN viruses were considered antigenically similar to the cell-passaged vaccine reference virus with more variability in relation to the egg-passaged vaccine virus [29] . Thereafter in 2016-17, clade 1A viruses were shown elsewhere (notably the United States) to have acquired a double amino acid deletion in HA1 antigenic sites 162-163 (∆162-163) distinguishing them antigenically from the cell-passaged clade 1A vaccine reference virus [18, 19, 30] ; however Victoria viruses did not contribute to lineage-specific VE analyses here for 2016-17 or 2017-18.
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Per phylogenetic analysis of SPSN viruses [29] . All sequenced clade 3 SPSN viruses bore the L172Q substitution and 90% (64/71) also bore M251V, both in non-antigenic sites. Six of seven viruses without M251V fell within a sub-cluster defined by L172Q with 3 other antigenic site substitutions reported elsewhere to be associated with re-assorted B(Victoria) neuraminidase [18, 19] . In general, clade 3 viruses characterized by the SPSN and elsewhere were not considered antigenically drifted in their HA [18, 19, 27] . Per phylogenetic analysis of SPSN viruses. All sequenced clade 3 viruses fell in the major subgroup defined by L172Q and M251V nonantigenic site substitutions. A subset bore other substitutions (e.g. V73M (120-loop) + Q122K (120-loop) + T181A in 11/194 (6%)). In general, clade 3 viruses characterized by the SPSN and elsewhere were not considered antigenically drifted in their HA [18, 19] . 
Supplement 2 Influenza vaccine and vaccine effectiveness (VE) -methods and details
Influenza vaccines
Among participating provinces (Alberta, British Columbia (BC), Ontario and Quebec) of the Canadian Sentinel Practitioner Surveillance Network (SPSN), influenza vaccine was available free of charge across the study period (2010-11 to 2017-18) to all citizens ≥ 6 months of age in Alberta and Ontario. In BC and Quebec the vaccine was provided free of charge to individuals considered to be at high risk of serious influenza complications, as well as to their close contacts and care givers [24] [25] [26] [27] [28] [29] .
Most influenza vaccines used in SPSN provinces across the study period were split, unadjuvanted, inactivated formulations; however, other available vaccine products were subunit, including MF59-adjuvanted subunit vaccine for elderly adults ≥ 65-years-old, or live attenuated influenza vaccine (LAIV), primarily for children. Prior to 2014-15, only trivalent influenza vaccines (TIV) were authorized for use in Canada. Quadrivalent influenza vaccine (QIV) first became authorized for use in Canada in 2014-15 as LAIV and in 2015-16 as inactivated formulation, both primarily for children. As shown below in Table 2A , TIV comprised the majority (>70%) of all publicly funded influenza vaccine doses purchased for the annual influenza immunization campaign by SPSN provinces overall across the study period. However, in 2016-17 and 2017-18 most doses in Alberta were QIV (>75% and >95% of doses, respectively) while QIV remained limited (primarily for children) in the other SPSN provinces both seasons (<15% and <25% of doses, respectively). 1 Proportions are based upon influenza vaccine doses purchased for the publicly funded influenza immunization campaign which provides the vast majority of influenza vaccine doses administered each year in Canada. By way of illustration, vaccine purchase per capita for Canada through the publicly funded program corresponds well with other sources of immunization coverage data for Canada [31, 32] , including the proportion self-reporting vaccination among test-negative controls displayed for the current study (in Supplement Table 3 ), each indicating that about 30-40% of the Canadian population (including across SPSN provinces) receive influenza vaccine annually. Information on privately purchased vaccines is not otherwise available but is not anticipated to much alter the above proportionate distributions. Although QIV was primarily targeted to children (except in the province of Alberta in 2016-17 and 2017-18), information is not available for TIV vs. QIV distribution by age and is summarized based on overall publicly-funded doses distributed.
Influenza vaccine manufacturing for Canada was egg-based throughout the study period.
Vaccine strains recommended each season by the World Health Organization (WHO) as TIV and QIV components are displayed in Table 2B below, including cell-passaged prototype reference and egg-adapted high-growth reassortant (HGR) strains. 1 TIV components are displayed in unshaded cells and bold font. Grey shading indicates that the specified strain was included only as a component of QIV that season. "-" indicates no Yamagata-containing TIV or QIV was recommended that season.
Vaccine effectiveness (VE) estimation
Participants were outpatients ≥1-year-old presenting to community-based sentinel practitioner sites in Alberta, BC, Ontario and Quebec within 7 days of onset of influenza-like illness (ILI) with specimen collection between January and April each season. ILI was defined by fever and cough and one or more of sore throat, myalgia, arthralgia or prostration. After the 2010-11 season, fever was not required for elderly adults ≥65-years-old.
Patient data, including vaccination status, were recorded on the laboratory requisition questionnaire by the sentinel practitioner at the time of nasal/nasopharyngeal specimen collection, prior to influenza diagnosis. Vaccination status was based on patient (or guardian) report but may have also been documented in the physician's records. Patients were considered vaccinated if they received seasonal influenza vaccine ≥2 weeks before symptom onset. Ageappropriate one-or two-dose influenza vaccine receipt was not further queried for children.
Cases tested positive for the specified influenza B lineage; controls tested negative for any influenza virus. Odds ratios (ORs) for influenza test positivity (by influenza B lineage) comparing vaccinated to unvaccinated patients were derived using logistic regression according to a test-negative study design. VE was derived as (1 -OR) X 100%. Patients were excluded from VE analyses if their specimens were collected outside the January -April analysis period, if they were <1-year-old, did not meet the ILI case definition or presented > 7 days since ILI onset, were vaccinated <2 weeks before ILI onset or were missing vaccination status, timing or covariate information. Except where specifically indicated otherwise, all analyses were adjusted for the following covariates: age group (1-8; 9-19; 20-49; 50-64; ≥65 years), sex (male/female), comorbidity (yes/no), province (Alberta, British Columbia, Ontario, Quebec), specimen collection interval (0-4 or 5-7 days from ILI onset) and calendar time based on week of specimen collection (cubic B-spline with 3 equally spaced knots) or else month where specified.
Negative interference was explored during seasons for which the TIV component was unchanged and lineage-or clade-mismatched to circulating viruses (i.e. 2011-12, 2014-15 and 2017-18). These secondary VE analyses were additionally restricted to patients ≥9-years-old with complete information for both current and prior season's vaccination. To derive VE by current and/or prior season's vaccination, vaccine status was specified in the model as an indicator variable, classified into four mutually exclusive groups: (1) unvaccinated both seasons (reference); (2) vaccinated prior but not current season; (3) vaccinated current but not prior season; and (4) vaccinated both current and prior season. Odds ratios for lineage-specific influenza B illness for each of these vaccination subgroups were also separately derived relative to current season only vaccine recipients as the reference group. These secondary vaccination subgroup analyses were adjusted as for the primary VE analysis, except where otherwise specified, and with the same exclusion criteria but with patients <9-years-old and missing information for prior season's vaccination status additionally excluded. 2 Relative to participants unvaccinated both seasons. Analyses restricted to participants ≥9 years old with complete information for current and prior season's vaccination status. VE adjusted for age group (1-8; 9-19; 20-49; 50-64; ≥65 years), sex (male/female), comorbidity (yes/no), province (Alberta, British Columbia, Ontario, Quebec), specimen collection interval (0-4 or 5-7 days from influenza-like illness (ILI) onset) and week of specimen collection (cubic B-spline with 3 equally spaced knots) except for Yamagata-lineage estimates in 2011-12 for which calendar time adjustment was based on month of specimen collection owing to limited sample size.
3 VE estimates presented here may not be directly comparable to overall VE estimates presented in the main manuscript or in prior publications [25, 28] owing to differences in the subset analyzed (participants ≥9 years old with complete information for current and prior season's vaccination status and restriction to the January to April period) as well as increased variability with reduced sample size, especially among those vaccinated current season only. 4 Sequencing of circulating influenza B viruses was not undertaken prior to the 2013-14 season. See Supplement Table 1 for details related to virological characterization in 2011-12. 5 Yamagata clade 2 and clade 3 viruses can likely be considered antigenically distinct but with some variation in cross-reactivity based on antisera used [18, 19] . 6 Excluding the province of Alberta (owing to greater quadrivalent influenza vaccine (QIV) use in 2017-18), adjusted VE estimates were 28% (95%CI=-10-53%) for prior only, 22% (95%CI=-34-54%) for current only and 40% (95%CI=19-55%) for current and prior season's vaccine receipt. 
